This evidence prompted medical societies (such as the American Diabetes Association) to include GLP-1 in their diabetes care recommendations
Smaller and slower meals are the sensible response, titration pace is the powerful one, and fibre belongs to the problem that comes after this one, not to this one
The decision to continue or discontinue GLP-1 therapy should be made collaboratively between the patient and their healthcare team, weighing the metabolic benefits against the risk of recurrent biliary symptoms
J Neural Transm (Vienna) , 115: 15451556, 2008
Documented symptomatic hypoglycemia (glucose of 70 mg/dL or less) was reported in 16.7% to 29.8% of patients receiving semaglutide, and severe or blood glucose confirmed symptomatic hypoglycemia (glucose of 56 mg/dL or less) was reported in 8.3% to 10.7% of patients receiving semaglutide
An appropriately composed KD can minimize side effects (257)